SIC
JAZZ icon

Samalin Investment Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Samalin Investment Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50
Closed -$7K – 344
2019
Q4 		$7K Buy
+50
New +$6.8K 0.01% 453

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Samalin Investment Counsel's JAZZ Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 50 shares — an estimated $7K sold.

Samalin Investment Counsel first reported a position in JAZZ in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 50 Jazz Pharmaceuticals shares in Q1 2020, an estimated $7K.
  • Samalin Investment Counsel first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Jazz Pharmaceuticals position peaked at $7K in Q4 2019.
  • 407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.